Nucleotide analogs are a major class of therapeutic agents that interfere with nucleic acid synthesis. They are structurally similar to natural nucleotides but incorporate modifications that disrupt normal nucleotide metabolism, DNA replication, or RNA transcription.
Mechanism of Action
Nucleotide analogs are prodrugs that require intracellular activation to their triphosphate forms. Cellular kinases sequentially phosphorylate the nucleoside analog to the monophosphate, diphosphate, and triphosphate. The triphosphate is the active species that competes with natural nucleotides for incorporation by DNA or RNA polymerases, similar to how dNTPs are used in PCR.
Once incorporated, the analog can block further chain elongation, particularly if lacking a 3-prime hydroxyl group. Chain terminators such as acyclovir and azidothymidine are obligate chain terminators because they lack the 3-prime hydroxyl needed for phosphodiester bond formation, a principle also exploited in DNA sequencing. Other analogs are incorporated internally but cause stalling, mispairing, or altered DNA structure that triggers apoptosis.
Anticancer Agents
Antimetabolites targeting nucleotide synthesis were among the first effective chemotherapeutic agents. Methotrexate inhibits dihydrofolate reductase, depleting tetrahydrofolate and blocking thymidylate and purine synthesis. It is used in leukemia, lymphoma, and autoimmune diseases. Pemetrexed is a newer antifolate that also inhibits thymidylate synthase.
5-Fluorouracil is converted to FUTP, which is incorporated into RNA and disrupts RNA processing, and to FdUMP, which forms a stable ternary complex with thymidylate synthase and inhibits dTMP synthesis. Capecitabine is an oral prodrug of 5-FU. These drugs treat colorectal, breast, and other cancers. Cytarabine is a cytidine analog used in acute myeloid leukemia. Gemcitabine, a difluorinated deoxycytidine analog, treats pancreatic, lung, and ovarian cancers. Fludarabine, a purine analog, is used in chronic lymphocytic leukemia.
Antiviral Agents
Nucleoside analogs are the backbone of antiviral therapy for herpesviruses, HIV, and hepatitis viruses. Acyclovir, phosphorylated by the HSV thymidine kinase, is a highly selective inhibitor of herpes simplex and varicella-zoster viruses. Ganciclovir is used for cytomegalovirus. Valacyclovir is the oral prodrug of acyclovir.
For HIV, nucleoside reverse transcriptase inhibitors were the first class of antiretroviral drugs. Zidovudine was the first approved HIV drug. Tenofovir, a nucleotide analog, is a cornerstone of current HIV therapy. These drugs are obligate chain terminators because they lack the 3-prime hydroxyl. They are used in combination with other antiretroviral classes to prevent resistance.
For hepatitis B, entecavir and tenofovir are first-line treatments. For hepatitis C, sofosbuvir, a uridine nucleotide analog, was a breakthrough, achieving cure rates over 95% when combined with other direct-acting antivirals. Remdesivir, an adenosine analog, was used against SARS-CoV-2 during the COVID-19 pandemic.
Resistance Mechanisms
Resistance to nucleotide analogs develops through several mechanisms. Mutations in the target polymerase reduce analog binding while maintaining natural nucleotide incorporation. The M184V mutation in HIV reverse transcriptase confers resistance to lamivudine. Mutations that increase proofreading activity, such as in herpes simplex virus DNA polymerase, can excise incorporated analogs. Increased expression of the target enzyme, decreased activation, or increased efflux can also cause resistance.
Selectivity and Toxicity
Selectivity for viral or cancer cells depends on differences in kinase expression, polymerase specificity, and metabolic activation. HSV thymidine kinase phosphorylates acyclovir much more efficiently than host cell kinases, providing selectivity. Cancer cells have altered nucleotide metabolism that increases analog activation.
Toxicity arises from incorporation into mitochondrial or nuclear DNA of normal cells. Mitochondrial toxicity from NRTIs causes lactic acidosis, peripheral neuropathy, and lipodystrophy. Myelosuppression is common with anticancer nucleoside analogs. Hand-foot syndrome occurs with 5-FU. Drug interactions can occur through competition for activation or degradation pathways.
Prodrug Strategies
Prodrug approaches improve oral bioavailability, cellular uptake, and activation. Valacyclovir is the valyl ester prodrug of acyclovir with improved oral absorption. Tenofovir alafenamide is a phosphonamidate prodrug that delivers tenofovir more efficiently to target cells. Baloxavir marboxil is a prodrug of a cap-dependent endonuclease inhibitor for influenza. These strategies continue to improve the therapeutic index of nucleotide analogs.
